The GLP-1 antagonist, exendin 939, regulates nociception via TRPV1 modulation Exendin 939, a synthetic peptide, functions as a specific and competitive antagonist of GLP-1 38
Consistent results delivered everyday across multiple InjectCo locations
Reducing the impact of these factors and preserving a healthy GI tract is critical for maintaining long-term health
The FDA drug interaction guidance for the GLP-1R agonist class specifies that levothyroxine, cyclosporine, and immunosuppressants should be taken at a fixed time interval relative to injection day, and therapeutic drug levels should be measured at weeks 4 and 12 during titration [11, 19]
The topological properties of the drug-disease network were analyzed using Cytoscape software, as demonstrated in Figure 5D